Balanced news tone
News Sentiment
ERAS sentiment intelligence
Erasca Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
48
Balanced news tone
47 relevant articles
News tone and price action are not far from neutral.
83/100 classification confidence.
directly relevant articles
high-authority source matches
+0.3% over one week, +31.9% over four weeks, trend active, and materially above fair value.
Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
83/100 classification
One-week reaction
0.3%
Price digesting
Trend fit
Trend active
31.9% over four weeks
Fair value
343.5%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
5
Neutral
37
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Direct company coverage
Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 Jul 2026 03:24
- Source
- Market source
PR Newswire
Direct company coverage
ERAS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Erasca Class Action Lawsuit
- Tone
- Negative 18/100
- Event
- Regulatory and legal
- Published
- 16 Jul 2026 00:00
- Source
- PR Newswire
marketscreener.com
Direct company coverage
Erasca Closes $632.5 Million Upsized Common Stock Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:29
- Source
- marketscreener.com
The Globe and Mail
Direct company coverage
Analysts Offer Insights on Healthcare Companies: Erasca (ERAS) and Tenet Healthcare (THC)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:18
- Source
- The Globe and Mail
GlobeNewswire
Direct company coverage
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:01
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Erasca intends to use offering proceeds for oncology drug research
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:01
- Source
- Stock Titan
Market source
Direct company coverage
Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 15:13
- Source
- Market source
Simply Wall St.
Direct company coverage
Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 14:10
- Source
- Simply Wall St.
Morningstar
Direct company coverage
ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
- Tone
- Negative 18/100
- Event
- Regulatory and legal
- Published
- 15 Jul 2026 14:07
- Source
- Morningstar
simplywall.st
Direct company coverage
Is Erasca (ERAS) Stock Trading At A Premium After New Trial Data?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 09:02
- Source
- simplywall.st
Insider Monkey
Direct company coverage
Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results
- Tone
- Positive 58/100
- Event
- Earnings
- Published
- 14 Jul 2026 23:40
- Source
- Insider Monkey
Stock Titan
Direct company coverage
Erasca (Nasdaq: ERAS) prices $550.0M upsized public stock sale
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 21:03
- Source
- Stock Titan
Quiver Quantitative
Direct company coverage
Why Erasca (ERAS) Stock Is Up Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 18:36
- Source
- Quiver Quantitative
scanx.trade
Direct company coverage
Erasca investors face August 10 deadline in $11.59 per share securities fraud suit
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 12:27
- Source
- scanx.trade
MT Newswires
Direct company coverage
Erasca Prices Upsized Public Offering of $550 Million
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 08:29
- Source
- MT Newswires
Moomoo
Direct company coverage
Erasca Plans $500 Million Underwritten Offering of Common Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 04:31
- Source
- Moomoo
Moomoo
Direct company coverage
Erasca Offering All Shares to Be Sold >ERAS
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 03:50
- Source
- Moomoo
Stock Titan
Direct company coverage
Erasca Plans to Use $550M Offering Proceeds for Drug Development
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 03:12
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Erasca Announces Pricing of Upsized Public Offering of Common Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 03:10
- Source
- GlobeNewswire
Moomoo
Direct company coverage
Press Release: Erasca Announces Pricing of Upsized Public Offering of Common Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 03:10
- Source
- Moomoo
Stock Titan
Direct company coverage
Erasca, Inc. (NASDAQ: ERAS) targets $500M stock sale to fund pipeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 21:24
- Source
- Stock Titan
Quiver Quantitative
Direct company coverage
Erasca Announces Proposed $500 Million Public Offering of Common Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:30
- Source
- Quiver Quantitative
GlobeNewswire
Direct company coverage
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:19
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Cancer drug developer Erasca plans $500M stock sale, plus $75M option
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:19
- Source
- Stock Titan
Stock Titan
Direct company coverage
Erasca, Inc. (NASDAQ: ERAS) sets up shelf to issue stock, debt and warrants
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 13 Jul 2026 20:16
- Source
- Stock Titan
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
simplywall.st
Direct company coverage
Does Erasca’s Shift Into Russell Growth Indexes (ERAS) Quietly Redefine Its Biotech Investment Story?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jul 2026 17:54
- Source
- simplywall.st
simplywall.st
Direct company coverage
Is Erasca (ERAS) Pricey On Its Lawsuit And ERAS 0015 Risks?
- Tone
- Negative 18/100
- Event
- Regulatory and legal
- Published
- 07 Jul 2026 18:42
- Source
- simplywall.st
The Globe and Mail
Direct company coverage
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 02 Jul 2026 21:48
- Source
- The Globe and Mail
Stock Titan
Direct company coverage
Erasca (NASDAQ: ERAS) investors back board slate and KPMG auditor
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 07:00
- Source
- Stock Titan